Emrelis access in Qatar: the MOPH-PD named-patient pathway
How patients in the State of Qatar legally obtain Emrelis (telisotuzumab vedotin-tllv) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Qatar access Emrelis (telisotuzumab vedotin-tllv) for adult patients with previously treated, locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression through the MOPH-PD named-patient pathway, a the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health-administered mechanism that allows a Qatari-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in QAR.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Qatari patients need Emrelis through the named-patient pathway
The State of Qatar operates a structured pharmaceutical regulatory environment. Emrelis (telisotuzumab vedotin-tllv) is regulated through MOPH-PD (the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health) channels, and a Qatari family asking for Emrelis is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Emrelis's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Qatar or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MOPH-PD named-patient pathway is the mechanism that connects a Qatari-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Emrelis is an antibody-drug conjugate (ADC) combining a humanised anti-c-Met monoclonal antibody with the microtubule-disrupting payload monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker, delivering targeted cytotoxic payload to c-Met-high tumour cells, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Emrelis in Qatar
Emrelis (telisotuzumab vedotin-tllv; AbbVie) is an antibody-drug conjugate (ADC) combining a humanised anti-c-Met monoclonal antibody with the microtubule-disrupting payload monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker. The drug received FDA accelerated approval in May 2025 for adult patients with previously treated, locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression (as determined by an FDA-approved IHC test).
As of 2026-05-31, no public Qatar MOPH record of a marketing authorisation for telisotuzumab vedotin has been observed; the drug is too recent in the global register for a routine Qatar registration timeline. Access proceeds through the MOPH Department of Pharmacy and Drug Control as a named-patient file under Qatar Law No. 3 of 1983.
The c-Met IHC scoring prerequisite is determinative. The file specifies the c-Met IHC result by the FDA-approved companion-diagnostic methodology, the EGFR-mutation-status documentation (if EGFR mutation positive, prior EGFR TKI therapy is referenced), the prior systemic therapy history, the radiographic response history, and the dosing plan (telisotuzumab vedotin 1.9 mg/kg IV every 2 weeks).
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Qatar where Emrelis is dispensed
Telisotuzumab vedotin is an adult medical oncology infusion product for non-squamous NSCLC. Qatar adult thoracic-oncology infusion concentrates at:
- Hamad Medical Corporation - National Center for Cancer Care and Research (NCCCR), Doha - Department of Medical Oncology with thoracic-oncology subspecialty; the principal adult oncology centre in Qatar. NCCCR maintains in-house IHC and molecular pathology including c-Met IHC. Source: NCCCR / HMC.
- Hamad General Hospital, Doha - Department of Pulmonology / Internal Medicine for diagnostic work-up; chemotherapy infusion at NCCCR after referral.
- Al-Ahli Hospital, Doha - private tertiary multi-specialty with medical oncology service for expatriate / insured cases.
- Doha Clinic Hospital, Doha - private multi-specialty hospital.
Note: Sidra Medicine is paediatric-only and is NOT a dispensing centre for adult NSCLC therapy. Adult thoracic-oncology cases in Qatar route exclusively to NCCCR / HMC and the private multi-specialty hospitals.
Local pricing reference for Emrelis in Qatar
US WAC reference for Emrelis (telisotuzumab vedotin, 40 mg and 100 mg single-dose vials) is in the order of USD 9,000 to USD 11,000 per body-surface-area-dosed cycle for a typical 70 kg adult at 1.9 mg/kg every 2 weeks. The annual reference is in the order of USD 230,000 to USD 290,000 at 26 cycles per year. Source: Emrelis FDA Prescribing Information.
No public QAR reference price for telisotuzumab vedotin has been observed on MOPH or NCCCR published lists as of 2026-05-31. QAR is pegged to USD at approximately 3.64 QAR per USD; the per-cycle indicative QAR reference is approximately QAR 33,000 to QAR 40,000.
Price snapshot date: 2026-05-31. Infusion-suite charges, c-Met IHC companion-diagnostic billing, and ILD / pneumonitis monitoring imaging are billed separately by NCCCR.
Country-specific access barriers for Emrelis in Qatar
The first practical barrier is the c-Met IHC companion-diagnostic prerequisite. NCCCR runs c-Met IHC on the FDA-approved methodology; turnaround is typically one week. Without confirmed high c-Met protein overexpression on the FDA-approved IHC test, the FDA label is not met and the file is incomplete.
Public-sector funding for novel ADC therapy in Qatar: HMC NCCCR's funding pathway covers Qatari nationals (approximately 12% of the population) through the national oncology budget; eligibility includes both the indication match and the molecular biomarker confirmation. For expatriate residents (approximately 88% of the population), private insurance (QLM, AXA Gulf Qatar, Daman, Allianz Care, Bupa Global) coverage of novel ADCs is policy-specific; pre-authorisation is universally required.
The peripheral-neuropathy pharmacovigilance signal (MMAE class effect) and the interstitial-lung-disease / pneumonitis signal in the FDA label drive the monitoring axis. NCCCR's thoracic-oncology team operates a standardised PN-grading and dose-modification protocol; baseline chest CT and serial pulse-oximetry surveillance is documented in the dispensing-pharmacy clinical pathway.
Cold-chain (2 to 8 degree Celsius) is required for the prefilled vial; Doha airport handles refrigerated pharmaceutical clearance routinely through HMC and the private hospital cold-chain channels. Each MOPH permit covers a defined supply window; continuous-therapy patients re-apply per cycle, typically every 8 to 12 weeks.
Recent local regulatory news touching Emrelis or its drug class in Qatar
No MOPH bulletin specifically naming telisotuzumab vedotin or the c-Met-targeted ADC class has been observed in the last twelve months on the MOPH media centre as of 2026-05-31. Adjacent context:
- FDA accelerated approval of telisotuzumab vedotin in May 2025 is the recent regulatory event; the post-marketing confirmatory trial is ongoing and the FDA will update labelling on the confirmatory data. Source: FDA Drugs@FDA database.
- NCCCR continues to publish thoracic-oncology service updates including molecular-pathology testing expansion. Source: NCCCR / HMC.
What your physician needs to provide
For a Qatari-licensed specialist prescribing Emrelis through the MOPH-PD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for adult patients with previously treated, locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Emrelis is the appropriate next step given an antibody-drug conjugate (ADC) combining a humanised anti-c-Met monoclonal antibody with the microtubule-disrupting payload monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker, delivering targeted cytotoxic payload to c-Met-high tumour cells.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Emrelis (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Qatari license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Emrelis in Qatar
Will Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Emrelis is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MOPH-PD? The MOPH-PD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MOPH-PD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Qatari-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Qatar Council for Healthcare Practitioners (QCHP) and the MOPH verifies the active license; the MOPH-PD application records both the prescribing physician and the dispensing facility.
Can I receive Emrelis at home? The dispensing facility must be Qatari-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Emrelis cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MOPH-PD, and we do not replace your dispensing pharmacy. For Emrelis specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Qatar, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Emrelis case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MOPH-PD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Emrelis is dosed as an intravenous infusion every two weeks; the dispensing centre monitors for peripheral neuropathy, ocular surface toxicity, interstitial lung disease, and infusion reactions per the FDA label.
Next step
If your Qatari physician has prescribed Emrelis and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.